Jeremy G. Chadwick, Chief Operating Officer at Kymera Therapeutics, Inc. (KYMR), sold 51,516 shares at $82.13 ($4.3M) on 2026-03-11, disclosed to the SEC on 2026-03-11.
Open-market sale of $4.3M KYMR by Chief Operating Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $82.13 | 1,765 | $145K | 3.4% |
| 2 | $82.13 | 1,765 | $145K | 3.4% |
| 3 | $83.10 | 12,882 | $1.1M | 24.9% |
| 4 | $83.10 | 12,882 | $1.1M | 24.9% |
| 5 | $83.72 | 11,111 | $930K | 21.7% |
| 6 | $83.72 | 11,111 |
| $930K |
| 21.7% |
| Total | $83.30 avg | 51,516 | $4.3M | 100% |
| Filing → |
| KYMR | SELL | 2026-04-16 | $590K | — | Filing → |
| KYMR | SELL | 2026-04-01 | $1.9M | — | Filing → |
| KYMR | SELL | 2026-03-25 | $18.0M | — | Filing → |